Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Aduro Biotech Inc.
Headquarters: Berkeley, CA, United States of America
Website: N/A
Year Founded: 2000
Status: Reverse-merged
BioCentury | Aug 23, 2024
Emerging Company Profile
Borealis: Versant, Novartis launch Chinook’s RNA-targeting sequel
The research team behind Chinook are taking on renal diseases with cell type-specific delivery of oligonucleotide therapies.
BioCentury | Jun 12, 2023
Deals
Seeking high-value drugs, Novartis adds kidney franchise in $3.2B Chinook takeout
Biotech’s later-stage candidates give pharma two chances at a blockbuster, starting with IgA nephropathy indication amid rising competition
BioCentury | Aug 10, 2022
Management Tracks
New CMOs at Arcus, Enanta
Plus Lamba becomes CFO at ImmPACT, and updates from Appia Bio and Quanterix
BioCentury | Aug 27, 2021
Distillery Therapeutics
STING agonism as treatment for pain from bone metastases
BioCentury | Jul 20, 2021
Management Tracks
Arcus’ Grossman to join Gilead as SVP of oncology clinical research
Plus: Nuyten joining Nektar and updates from Janux, UKI2S, Arena and ArsenalBio
BioCentury | Jun 23, 2021
Emerging Company Profile
Abata: engineering targeted Treg cell therapies with TCRs
Emerging Company Profile: Third Rock launches Abata with $95M series A to develop targeted Treg cell therapies for autoimmune disorders
BioCentury | Feb 25, 2021
Management Tracks
Promotions at Anokion and GlycoMimetics; Read to chair TriNetX and moves at Lava, PYC, Quotient, ImmunoSCAPE and Emergex
Anokion S.A. promoted Deborah Geraghty to president and CEO from COO following John Hohneker’s retirement from the Swiss autoimmune company. The company also promoted Raj Manchanda to chief
BioCentury | Nov 3, 2020
Management Tracks
Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more
Gene therapy developer Freeline Therapeutics Holdings plc (NASDAQ:FRLN) hired Mark Baldry as chief commercial officer. He previously held the same role at Wave Life Sciences Ltd. (NASDAQ:WVE).
BioCentury | Oct 6, 2020
Deals
Oct. 5 Quick Takes: BridgeBio reacquiring Eidos, Amgen KRAS data, after-hours tumbles for Iovance, Y-mAbs and more
BridgeBio reacquiring Eidos spinoutFour years after spinning out Eidos Therapeutics Inc. (NASDAQ:EIDX), BridgeBio Pharma Inc. (NASDAQ:BBIO) will acquire the 36.3% of that company it does not already
BioCentury | Aug 19, 2020
Finance
Aug. 18 Quick Takes: Chinook fuels up for NASDAQ liftoff; plus Kymera, Poseida, Albireo
Chinook hooks $106M, soon to test NASDAQ’s watersChinook Therapeutics Inc. raised $106 million in a venture round as it prepares to reverse-merge with Aduro Biotech Inc. (NASDAQ:ADRO). New
Items per page:
1 - 10 of 134